MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MacroGenics reports revenue growth and promising clinical updates in Q4

MacroGenics delivered strong financial performance with revenue growth and cost reductions in 2022.
The company faces challenges in study modifications, dose optimization, and patient evaluation for its key products.
Opportunities lie in expanding product studies, strategic partnerships, and optimizing treatment efficacy.
Overall, MacroGenics shows promise in financial stability, product development, and market positioning.

MacroGenics reports Q1 revenue growth amidst net loss challenges

MacroGenics showed mixed financial performance in Q1 2023 with revenue growth but a significant net loss.
The company's strengths lie in its anticipated cash runway, FDA approvals, and expected milestone payments.
Challenges include managing expenses, improving financial performance, and addressing analyst inquiries.
Opportunities exist in revenue growth, clinical programs, FDA approvals, and strategic partnerships.

MacroGenics reports Q2 results, projects strong pipeline growth ahead

MacroGenics' Q2 2023 performance reflects mixed financial results but strong progress in pipeline development and strategic partnerships.
The company's financial stability, ongoing innovation, and revenue potential position it well for future growth and value creation.
Challenges in data disclosure, enrollment criteria, and dose optimization require careful navigation, but present opportunities for market expansion and program enhancement.

MacroGenics reports improved Q3 earnings, eyes strategic partnerships for growth

MacroGenics demonstrated improved financial performance in Q3 2023, with a focus on cost management and strategic pipeline advancements.
The company's efforts to secure non-dilutive capital, explore partnerships, and drive innovation in ADC development position it for future growth.
Challenges lie in revenue generation, market differentiation, and resource allocation, but opportunities exist in collaborations, tumor type expansion, and technological advancements.

MacroGenics reports revenue decline but advances in clinical programs

MacroGenics faced a decline in revenue but made progress in its clinical programs and pipeline advancements.
Challenges include data transparency, patient enrollment, and managing treatment side effects.
Opportunities lie in potential Phase III trials, revenue growth prospects, and advancements in patient treatment.

MacroGenics reports strong Q1 results, eyes expansion and combination therapies

MacroGenics' Q1 2024 performance showed promising results with strong revenue and ongoing research advancements.
The company's focus on expanding studies, improving tolerability, and exploring combination therapies presents growth opportunities.
Challenges include ongoing investigations into safety protocols and evaluation of patient outcomes.
Overall, MacroGenics' strategic plans and positive efficacy outcomes position them well for future growth and development.

MacroGenics reports stellar Q3 earnings, CEO transition announced

MacroGenics delivered impressive financial results in Q3 2024, marked by substantial revenue growth, increased net income, and a solid cash balance supported by strategic initiatives.
While facing challenges in managing rising expenses and navigating a CEO transition, the company's diverse clinical pipeline and strong financial position present opportunities for future growth and innovation.
Investors should monitor how MacroGenics addresses cost management, sustains operational momentum during leadership changes, and capitalizes on its strengths to drive continued success in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

- Advisory committee meeting not required; PDUFA goal date unchanged

MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer

Rockville, MD, May  27, 2020  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to support registration in the U.S. of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule for patients with acute myeloid leukemia (AML) who are refractory to induction therapy.

MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia

Allogene Therapeutics Inc

Amgen

Arvinas Inc

CytomX Therapeutics

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe.

5 ASCO Abstracts Moving Biopharma Stocks

Rockville, MD, May  13, 2020  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results from two of its investigational pipeline molecules. Data covering safety and preliminary anti-tumor activity from the Phase 1 dose escalation and expansion clinical trial of MGD013, a bispecific, tetravalent DART® molecule binding PD-1 and LAG-3, and the Phase 1 dose expansion study of MGC018, an antibody-drug conjugate (ADC) targeting B7-H3, will be presented at the American Society of Clinical Oncology (ASCO) upcoming  ASCO20 Virtual Scientific Program  to be held May 29-31, 2020.

MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in MacroGenics (MGNX) Stock?

Optimism is growing ahead of the release of abstracts this week for the upcoming ASCO 2020 conference.

Why MacroGenics Stock Jumped 29% Today

The price of MacroGenics Inc. (MGNX) shares has recently seen a huge jump. After providing an early glimpse of some of the earnings results on May 6, MacroGenics’s stock soared by more than 230% to a two-year high, bringing its market value to nearly $1 billion.

Optimism Runs High for MacroGenics

Protagonist Therapeutics

Stemline Therapeutics

Here's what's behind their impressive market performances.

3 Small-Cap Biotech Stocks That Surged Last Week

The company could receive an FDA go-ahead on its lead drug candidate as soon as this year.

Here's Why MacroGenics Stock Is Skyrocketing 171% Today

MacroGenics Inc (NASDAQ: MGNX) reported Tuesday after the close with forecast-beating first-quarter results and said it has adequate cash to operate into 2022.

MacroGenics Analyst Sees Multiple Sources Of Upside, Biopharma Rallies After Q1 Update

MacroGenics' (MGNX) CEO Scott Koenig on Q1 2020 Results - Earnings Call Transcript

MacroGenics (MGNX) delivered earnings and revenue surprises of 9.90% and 84.12%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates

LeMaitre Vascular

QuidelOrtho Corp

Zynex Inc

An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.

Trump Pushes for US-Made Medical Products: 4 Winners

Rockville, MD, March  04, 2020  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that Jon Wigginton, M.D., Senior Vice President, Clinical Development & Chief Medical Officer, will be leaving the Company effective March 27, 2020 to pursue a new opportunity.

MacroGenics Announces Departure of Chief Medical Officer

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2019 Results - Earnings Call Transcript

MacroGenics (MGNX) delivered earnings and revenue surprises of 12.68% and 134.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

ROCKVILLE, MD, Feb.  10, 2020  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will attend the following investor conferences in February:

MacroGenics  to Participate in Upcoming Investor Conferences

Rockville, MD, Jan.  13, 2020  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2020, at 9:00 a.m. PT.

MacroGenics to Present at the J.P. Morgan Healthcare Conference

Rockville, MD, Jan.  09, 2020  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced its corporate and program priorities for 2020.

MacroGenics Outlines Corporate Priorities for 2020

ROCKVILLE, MD, Dec.  19, 2019  (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company has submitted a Biologics License Application (BLA) for margetuximab, an investigational, Fc-engineered, monoclonal antibody that targets HER2. The margetuximab BLA is for the treatment of patients with metastatic HER2-positive breast cancer in combination with chemotherapy. The submission is based on the safety and efficacy results of the pivotal phase 3 SOPHIA study, which were first presented at the 2019 American Society of Clinical Oncology annual meeting, with updated data recently presented at the 2019 San Antonio Breast Cancer Symposium.

MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA

Biologics License Application (BLA) submission to FDA expected before the end of 2019 Biologics License Application (BLA) submission to FDA expected before the end of 2019

MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Conference call scheduled for today at 8:00 p.m. ET Conference call scheduled for today at 8:00 p.m. ET

MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting

Rockville, MD, Dec.  02, 2019  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in a fire-side chat with the analyst at the Evercore ISI 2nd Annual HealthCONx Conference in Boston, MA on Tuesday, December 3, 2019, at 4:15 p.m. ET.

MacroGenics to Participate in the Evercore ISI HealthCONx Conference

ACADIA Pharma

Alector Inc

Amarin Corporation Plc

Avadel Pharma

Bausch Health Companies Inc

Biogen

Epizyme

G1 Therapeutics

Syros Pharmaceuticals

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.

Major Biopharma Catalysts on the December FDA Calendar

Industry watchers are skeptical that the company's lead drug candidate can succeed.

News for MacroGenics Stock (MGNX)